Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
19.08. | BiomX Inc: BiomX Provides Update on BX004 Phase 2b Trial for the Treatment of Patients with Cystic Fibrosis | 515 | GlobeNewswire (Europe) | U.S. FDA has placed a clinical hold on the Phase 2b study as it reviews data submitted by BiomX on third-party nebulizer used to deliver BX004; no concerns were raised in the clinical hold notification... ► Artikel lesen | |
13.08. | BiomX outlines BX004 Phase IIb results expected in Q1 2026 as BX211 advances toward registrational study | 1 | Seeking Alpha | ||
BIOMX Aktie jetzt für 0€ handeln | |||||
13.08. | BiomX Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
13.08. | BiomX GAAP EPS of -$0.19 | 3 | Seeking Alpha | ||
13.08. | BiomX Inc. - 8-K, Current Report | 1 | SEC Filings | ||
13.08. | BiomX Inc: BiomX Reports Second Quarter 2025 Financial Results and Provides Program Updates | 331 | GlobeNewswire (Europe) | Positive Phase 2 results for BX211 demonstrated >40% wound size reduction vs. placebo in diabetic foot osteomyelitis patients; Planning underway for potential registrational study Nature Communications... ► Artikel lesen | |
12.08. | What to Expect from BiomX's Earnings | 1 | Benzinga.com | ||
06.08. | BiomX Inc: BiomX to Report Second Quarter 2025 Financial Results and Program Updates on August 13, 2025 | 1 | GlobeNewswire (USA) | ||
30.07. | BiomX Inc. - 8-K, Current Report | 2 | SEC Filings | ||
15.07. | BiomX stock holds Buy rating at H.C. Wainwright as Phase 2b trial begins | 3 | Investing.com | ||
15.07. | BiomX stock maintains Buy rating at H.C. Wainwright with $15 price target | 1 | Investing.com | ||
14.07. | BiomX stock soars after initiating Phase 2b trial for cystic fibrosis therapy | 2 | Investing.com | ||
14.07. | BiomX-Aktie schießt nach Start von Phase-2b-Studie für Mukoviszidose-Therapie in die Höhe | 4 | Investing.com Deutsch | ||
14.07. | BiomX startet Phase-2b-Studie mit Phagentherapie gegen Infektionen bei Mukoviszidose | 1 | Investing.com Deutsch | ||
14.07. | BiomX begins phase 2b trial for phage therapy targeting CF infections | 1 | Investing.com | ||
14.07. | BiomX Inc: BiomX Announces Successful Initiation of Phase 2b Trial with First Patient Dosed in BX004 Program in Patients with Cystic Fibrosis | 208 | GlobeNewswire (Europe) | First patient dosing in Company's Phase 2b trial marks pivotal milestone in phage therapy development program targeting antibiotic-resistant lung infections in Cystic Fibrosis patients; topline results... ► Artikel lesen | |
08.07. | BiomX Inc. - 8-K, Current Report | 2 | SEC Filings | ||
09.06. | BiomX Inc. - 8-K, Current Report | 4 | SEC Filings | ||
16.05. | H.C. Wainwright cuts BiomX stock target to $15, maintains Buy | 6 | Investing.com | ||
15.05. | BiomX Inc. - 10-Q, Quarterly Report | 1 | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 90,45 | +0,06 % | Achtung Übernahmen! BioTechs wie Evotec, PanGenomic Health, Pfizer und BioNTech im Fokus | Die BioTech-Branche ist in Aufruhr! Mit dem Wegfall von Blockbuster-Patenten drohen kräftige Umsatzrückgänge, die strategisch kompensiert werden müssen. Angetrieben durch wirtschaftlichen Druck und... ► Artikel lesen | |
AMGEN | 255,00 | -0,33 % | ROUNDUP/Aktien New York Schluss: Gewinne - Drohender Shutdown lässt Anleger kalt | NEW YORK (dpa-AFX) - Die Anleger am US-Aktienmarkt sehen einem möglichen "Shutdown" gelassen entgegen. Die wichtigsten US-Indizes zeigten sich am Dienstag im New Yorker Börsenhandel nach einem insgesamt... ► Artikel lesen | |
INOVIO PHARMACEUTICALS | 2,140 | +4,90 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Inducement Grant Under Inducement Plan | PLYMOUTH MEETING, Pa., Oct. 2, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help... ► Artikel lesen | |
CARDIOL THERAPEUTICS | 0,910 | +0,33 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
12.08.2025 / 13:31 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen | |
PACIFIC BIOSCIENCES OF CALIFORNIA | 1,294 | +2,91 % | PacBio Enters Carrier Screening Market With PureTarget Expansion | ||
REDHILL BIOPHARMA | 1,930 | -13,06 % | RedHill Biopharma stock surges after court upholds $10M judgment | ||
FIBROGEN | 9,650 | -4,46 % | XFRA 1FG0: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
LEXAGENE | - | - | LexaGene Holdings Inc. - REVOKED, Commission order revoking Exchange Act registration [Section 12(j)] | ||
ALLAKOS | 0,255 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 15.05.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 15.05.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 15.05.2025.ISIN NameCA05259R1073 AUSTRALIS... ► Artikel lesen | |
VAXCYTE | 36,000 | -1,10 % | Vaxcyte, Inc.: Vaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and Services | New Agreement with Thermo Fisher Scientific Expands Domestic Capacity to Support Future Commercial Manufacturing of Vaxcyte's Broad-Spectrum Pneumococcal Conjugate Vaccine Candidates SAN CARLOS, Calif.... ► Artikel lesen | |
VERRICA PHARMACEUTICALS | 3,780 | -4,06 % | Verrica-Aktie springt nach Zulassung in Japan zweistellig nach oben | Die Aktie von Verrica Pharmaceuticals legte am Freitag um 14 Prozent zu. Auslöser war die Nachricht, dass der japanische Entwicklungspartner Torii Pharmaceutical die Zulassung des Mittels YCANTH (TO-208)... ► Artikel lesen | |
HOOKIPA PHARMA | 0,870 | +3,55 % | HOOKIPA Pharma Inc.: HOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common Stock | NEW YORK and VIENNA, July 18, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, "HOOKIPA"), a clinical-stage biopharmaceutical company developing next-generation immunotherapeutics for the... ► Artikel lesen | |
TAYSHA GENE THERAPIES | 4,770 | -2,25 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | DALLAS, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based... ► Artikel lesen | |
ADMA BIOLOGICS | 14,660 | +0,89 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
QIAGEN | 39,740 | +0,68 % | Kaum Impulse für die Qiagen NV-Aktie (37,58 €) | Wenig Kursbewegung zur Stunde bei dem Anteilsschein von Qiagen NV . Der jüngste Kurs betrug 37,58 Euro. Einen minimalen Wertanstieg von 0,17 Prozent zeigt die Kurstafel für der Anteilsschein von Qiagen... ► Artikel lesen |